Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
González-Bárcena
D
D
Pérez-Sánchez
P
P
Hernández-Meza
A R
AR
Rangel-García
N
N
Graef-Sánchez
A
A
Comaru-Schally
A M
AM
Schally
A V
AV
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000502:physiology*; D005951:Glucose Tolerance Test; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017329:Triptorelin Pamoate
D000970:Antineoplastic Agents; D001786:Blood Glucose; D007328:Insulin; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone